*****POST Riskreturn analysis to pecosbill quest
Post# of 30065
Posted On: 07/10/2014 4:00:49 AM
Re: Daveludlow #1620
*****POST
Riskreturn analysis to pecosbill question from another board.
"Hypothetically speaking ,What would a 10$B buyout do for our share price?"
If we were to be bought out today and we used an outstanding share figure of 800 million, our pps would be approximately $12 and a few cents! I don't think we'll hit a 10 billion market cap or get an offer for a 10 billion dollar buy out for a few years. It is possible in maybe 5 or 6 or 7 years. By that time LymPro's revenue will be approaching 1 billion per year. Lets assume our partner takes 20% of that leaving us with 800 million. If you multiply that times 8 to determine an appropriate market cap....that would put us at 6.4 billion. That could happen in 5 years. But by then we'll have MANF indications commercialized: Retinitis and Wolframs (Diabetes) Who knows what those indications could do to our market cap? So it is very possible that in 5 years we could have a combined market cap of 10 billion.
Riskreturn analysis to pecosbill question from another board.
"Hypothetically speaking ,What would a 10$B buyout do for our share price?"
If we were to be bought out today and we used an outstanding share figure of 800 million, our pps would be approximately $12 and a few cents! I don't think we'll hit a 10 billion market cap or get an offer for a 10 billion dollar buy out for a few years. It is possible in maybe 5 or 6 or 7 years. By that time LymPro's revenue will be approaching 1 billion per year. Lets assume our partner takes 20% of that leaving us with 800 million. If you multiply that times 8 to determine an appropriate market cap....that would put us at 6.4 billion. That could happen in 5 years. But by then we'll have MANF indications commercialized: Retinitis and Wolframs (Diabetes) Who knows what those indications could do to our market cap? So it is very possible that in 5 years we could have a combined market cap of 10 billion.
(0)
(0)